Dr Sabrina Sacconi (Côte d’Azur University, Nice, France) summarizes her top 3 highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023 in the field of myasthenia gravis, an area with significant unmet needs for treatment options. It is an exciting time for research in this area, with a number of important clinical trials in progress. Dr Sacconi summarizes some of the newest drugs in investigation.
Disclosures: Sabrina Sacconi is a consultant for Dyne therapeutics and Sanofi. She has received grant/research support from Roche, Biogen and Lupin, and is a member of the advisory board for UCB pharma, Sanofi, Fulcrum, Alexion and Roche.
Support: Interview and filming was supported by Touch Medical Media. The interview was conducted by Sophie Nickelson.
Filmed as highlight of EAN 2023.